Nabil F. Saba
纳比尔·萨巴
MD, FACP
Professor and Director, Head and Neck Medical Oncology Program教授及头颈肿瘤内科项目主任
👥Biography 个人简介
Nabil F. Saba, MD, FACP is Professor of Hematology and Medical Oncology and Director of the Head and Neck Medical Oncology Program at Emory University's Winship Cancer Institute. He is a nationally recognized expert in rare head and neck malignancies, with a particular focus on salivary gland carcinomas, thyroid cancer, and HER2/androgen receptor-driven tumors. Dr. Saba led and participated in landmark studies evaluating androgen receptor (AR) expression and anti-androgen therapy in salivary duct carcinoma and AR-positive salivary gland cancers, establishing AR as a therapeutic target in these rare malignancies. He also led early trials of anti-HER2 agents in HER2-amplified salivary gland tumors. An active member of multiple national cooperative groups (ECOG-ACRIN, NRG), he chairs the ECOG-ACRIN Head and Neck Committee and has pioneered clinical trial infrastructure for rare HNSCC subtypes.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Androgen Receptor Targeting in Salivary Duct Carcinoma
Led and co-led clinical studies demonstrating meaningful anti-tumor activity of androgen deprivation therapy and AR antagonists (e.g., enzalutamide, leuprolide + bicalutamide) in AR-positive salivary duct carcinoma and androgen receptor-positive salivary gland cancers.
HER2-Directed Therapy in Salivary Gland Carcinoma
Conducted phase II trials of trastuzumab-based regimens and ado-trastuzumab emtansine (T-DM1) in HER2-amplified/overexpressing salivary gland tumors, demonstrating clinical benefit and supporting HER2 testing as a routine practice.
ECOG-ACRIN Head and Neck Committee Leadership
As chair of the ECOG-ACRIN Head and Neck Committee, developed and launched national clinical trials in rare HNSCC subtypes for which no standard of care existed, greatly expanding treatment options for patients with salivary gland, nasopharyngeal, and other uncommon head and neck malignancies.
Predictive Biomarkers in Rare HNSCC
Established tissue-based biomarker programs for AR, HER2, NTRK, and RET alterations in rare HNSCC, enabling patient selection for targeted therapy trials and contributing to FDA-approved indications for larotrectinib, pralsetinib, and trastuzumab deruxtecan in these cancers.
Representative Works 代表性著作
Androgen deprivation therapy in patients with androgen receptor-expressing salivary gland carcinomas
Journal of Clinical Oncology (2019)
Phase II study demonstrating objective responses and disease control with leuprolide plus bicalutamide in androgen receptor-positive salivary gland carcinoma, establishing AR as an actionable target.
Trastuzumab and docetaxel in HER2-amplified salivary gland carcinoma
Head & Neck (2017)
Phase II trial evaluating trastuzumab plus docetaxel in HER2-amplified salivary gland cancers, providing response rate and survival data supporting HER2-directed therapy in this rare tumor.
Prevalence and therapeutic implications of androgen receptor expression and HER2 amplification in salivary gland carcinomas
Oral Oncology (2020)
Comprehensive biomarker survey of AR expression and HER2 amplification across salivary gland carcinoma subtypes, guiding molecular testing recommendations.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Hope S. Rugo
University of California, San Francisco (UCSF)
Maryam B. Lustberg
Yale School of Medicine / Yale Cancer Center
Sara M. Tolaney
Dana-Farber Cancer Institute / Harvard Medical School
Carlos H. Barrios
PUCRS (Pontifical Catholic University of Rio Grande do Sul) / Hospital São Lucas, Porto Alegre, Brazil
关注 纳比尔·萨巴 的研究动态
Follow Nabil F. Saba's research updates
留下邮箱，当我们发布与 Nabil F. Saba（Emory University / Winship Cancer Institute）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment